Boston Scientific Corporation $BSX Shares Acquired by Beese Fulmer Investment Management Inc.

Beese Fulmer Investment Management Inc. increased its position in Boston Scientific Corporation (NYSE:BSX) by 4,839.4% during the fourth quarter, Holdings Channel reports. The fund owned 222,026 shares of the medical equipment provider’s stock after purchasing an additional 217,531 shares during the quarter. Boston Scientific comprises approximately 1.2% of Beese Fulmer Investment Management Inc.’s investment portfolio, making the stock its 25th largest position. Beese Fulmer Investment Management Inc.’s holdings in Boston Scientific were worth $21,170,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Canada Post Corp Registered Pension Plan increased its holdings in shares of Boston Scientific by 6.7% in the 4th quarter. Canada Post Corp Registered Pension Plan now owns 57,803 shares of the medical equipment provider’s stock worth $5,512,000 after acquiring an additional 3,606 shares during the period. Dana Investment Advisors Inc. increased its holdings in shares of Boston Scientific by 12.8% in the 4th quarter. Dana Investment Advisors Inc. now owns 146,537 shares of the medical equipment provider’s stock worth $13,972,000 after acquiring an additional 16,674 shares during the period. Qsemble Capital Management LP increased its holdings in shares of Boston Scientific by 64.8% in the 4th quarter. Qsemble Capital Management LP now owns 127,966 shares of the medical equipment provider’s stock worth $12,202,000 after acquiring an additional 50,313 shares during the period. AlphaCore Capital LLC increased its holdings in shares of Boston Scientific by 23.1% in the 4th quarter. AlphaCore Capital LLC now owns 6,095 shares of the medical equipment provider’s stock worth $581,000 after acquiring an additional 1,145 shares during the period. Finally, Lockheed Martin Investment Management Co. grew its position in Boston Scientific by 12.0% in the 4th quarter. Lockheed Martin Investment Management Co. now owns 54,550 shares of the medical equipment provider’s stock valued at $5,201,000 after buying an additional 5,840 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

NYSE:BSX opened at $52.67 on Friday. Boston Scientific Corporation has a twelve month low of $52.52 and a twelve month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average of $63.40 and a 200-day moving average of $81.79. The firm has a market cap of $78.27 billion, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter last year, the firm posted $0.75 EPS. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on BSX shares. Canaccord Genuity Group decreased their target price on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, April 23rd. Daiwa Securities Group lowered shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Royal Bank Of Canada decreased their target price on shares of Boston Scientific from $105.00 to $100.00 and set an “outperform” rating for the company in a research report on Thursday, April 23rd. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $93.91.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.